TECX (Tectonic Therapeutic) Short Interest

View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Tectonic Therapeutic's Short Interest

For the Biotechnology subindustry, Tectonic Therapeutic's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tectonic Therapeutic's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's Short Interest distribution charts can be found below:

* The bar in red indicates where Tectonic Therapeutic's Short Interest falls into.

Save Embed

;

Save Embed

;

Tectonic Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472

Website

https://www.tectonictx.com

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.